Novel Rehabilitation Strategies to Improve Arm Function in Patients With

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the feasibility and preliminary effects of a novel treatment approach to improve arm function in patients with scleroderma who have upper extremity contractures. It is a Phase 1, one arm trial in which participants will be assessed at baseline, 4 weeks, and 8 weeks. The rehabilitation intervention will involve 8 individual sessions with an occupational therapist. Feasibility of the procedures is a major focus of this project.

Clinical Trial Description

Our specific aims are to:

1. Determine the feasibility of a novel rehabilitation strategy provided at the University of Michigan Scleroderma Clinic to scleroderma patients who have upper extremity contractures.

Investigators will assess 3 main aspects of the process that are key to the success of a larger study including the proportion of eligible people who enroll in the study, rate of adherence to the treatment protocol, and the time it takes to conduct sessions including treatment and outcome assessment completion. Based on a framework of recommendations for well-designed pilot studies [1], investigators have set the following criteria for success to examine these aspects:

1. At least 50% of participants who are eligible for the study will enroll.

2. At least 80% of participants will attend all treatment sessions.

3. The 3 sessions involving both treatment and outcome assessments will not last on average more than 2 hours.

2. Develop a standardized treatment manual to train therapists to provide this treatment to their patients.

A standardized treatment manual for therapists is a critical component needed to ensure consistency in a larger multi-site trial. This manual will be drafted for use in this study and refined as needed.

3. Establish preliminary effects of this 8-week rehabilitation program on improving arm function.

Investigators hypothesize that participants with scleroderma will have significant improvements in the QuickDASH disability measure at post test. Although the investigators think large effects will be shown, this study will allow us to determine estimates of the effects and the variability for power calculations in a multi-site trial. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02837549
Study type	Interventional
Source	University of Michigan
Contact
Status	Completed
Phase	N/A
Start date	July 2016
Completion date	September 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02798055` - Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis
Completed	`NCT01959815` - Novel Screening Strategies for Scleroderma PAH
Completed	`NCT03274076` - Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)	Phase 1/Phase 2
Completed	`NCT02915835` - Riociguat in Scleroderma Associated Digital Ulcers	Phase 2
Active, not recruiting	`NCT01895244` - Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis	Phase 2
Completed	`NCT00883129` - Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)	Phase 2
Completed	`NCT00930683` - A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma	Phase 1
Completed	`NCT00074568` - Scleroderma Registry
Recruiting	`NCT04797286` - Sildenafil for Early Pulmonary Vascular Disease in Scleroderma	Phase 2
Completed	`NCT03222492` - Brentuximab Vedotin for Systemic Sclerosis	Phase 1/Phase 2
Completed	`NCT03207997` - MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients	N/A
Recruiting	`NCT04464434` - Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis	Phase 4
Recruiting	`NCT04246528` - SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)	N/A
Completed	`NCT05080738` - Upper Extremity Home Exercises in Patients With Scleroderma	N/A
Recruiting	`NCT03726398` - CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH	Phase 2/Phase 3
Recruiting	`NCT05085444` - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma	Early Phase 1
Completed	`NCT02062125` - Calcinosis in a Single-Center Scleroderma Population
Completed	`NCT04588714` - Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention	N/A
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed	`NCT02835196` - Optical Elastography of Systemic Sclerosis Skin

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms